0000899243-22-017321.txt : 20220509
0000899243-22-017321.hdr.sgml : 20220509
20220509184609
ACCESSION NUMBER: 0000899243-22-017321
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220505
FILED AS OF DATE: 20220509
DATE AS OF CHANGE: 20220509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ACKERMANN CHRISTINA
CENTRAL INDEX KEY: 0001681871
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41380
FILM NUMBER: 22906678
MAIL ADDRESS:
STREET 1: 400 SOMERSET CORPORATE BOULEVARD
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bausch & Lomb Corp
CENTRAL INDEX KEY: 0001860742
STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 520 APPLEWOOD CRESCENT
CITY: VAUGHAN
STATE: A6
ZIP: L4K 4B4
BUSINESS PHONE: 908-541-5456
MAIL ADDRESS:
STREET 1: 520 APPLEWOOD CRESCENT
CITY: VAUGHAN
STATE: A6
ZIP: L4K 4B4
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-05
0
0001860742
Bausch & Lomb Corp
BLCO
0001681871
ACKERMANN CHRISTINA
C/O BAUSCH + LOMB CORPORATION
520 APPLEWOOD CRESCENT, VAUGHAN
VAUGHAN
A6
L4K 4B4
ONTARIO, CANADA
0
1
0
0
Please see remarks
Common Shares, No Par Value
2022-05-05
4
A
0
83333
0.00
A
83333
D
Non-Qualified Stock Options (right to purchase)
18.00
2022-05-05
4
A
0
329670
0.00
A
Common Shares, No Par Value
329670
329670
D
Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan"). Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation (the "Company").
Reflects the grant of stock options to purchase Common Shares under the Plan.
The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement.
The stock options will expire on the tenth anniversary of the grant date.
The Reporting Person's title as an officer of the Issuer is Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals.
/s/ Debra E. Levin, attorney-in-fact
2022-05-09